Review of Promotional Materials Sample Clauses

Review of Promotional Materials. All Materials must be approved by both parties, such approval or disapproval not to be unreasonably withheld. Each party will notify the other in writing of its approval of a submitted item within ten (10) business days of receipt. Specific reasons must be given for disapproval. In the event the reviewing party has not notified the submitting party of its approval or disapproval within the ten (10) day period, the submitting party will notify the reviewing party in writing of that fact. Upon receipt of such notice, the reviewing party will have until the end of the next business day to either approve or disapprove the item. If the submitting party resubmits an item for review incorporating changes requested by the reviewing party, the reviewing party will notify the submitting party of its approval or disapproval within ten (10) business days of receipt of the resubmission. Failure to disapprove within a time frame set forth above does not constitute approval.
Sample 1Sample 2
AutoNDA by SimpleDocs
Review of Promotional Materials. All advertising and promotional materials used in connection with the Product, including, but not limited to, fulfillment kits, brochures, newsletters, inserts, telemarketing scripts, customer correspondence and form letters, must be approved by both parties, such approval or disapproval not to be unreasonably withheld. Each party will notify the other in writing of its approval of a submitted item within ten (10) business days of receipt. Specific reasons must be given for disapproval. In the event the reviewing party has not notified the submitting party of its approval or disapproval within the ten (10) day period, the submitting party will notify the reviewing party in writing of that fact. Upon receipt of such notice, the reviewing party will have until the end of the next business day to either approve or disapprove the item. If the reviewing party has not responded by the end of the next business day, the item will be deemed approved. If the submitting party resubmits an item for review incorporating changes requested by the reviewing party, the reviewing party will notify the submitting party of its approval or disapproval within five (5) business days of receipt of the resubmission.
Sample 1Sample 2
Review of Promotional Materials. The Sub-Adviser shall provide to the Adviser, upon reasonable request, information relating to the Sub-Adviser and its services to the Funds for inclusion in any promotional or disclosure materials relating to the Funds. Neither the Adviser, the Trust nor the Funds will use the Sub-Adviser's name, logo or make any statements relating to the Sub-Adviser or its affiliates in any promotional or disclosure materials unless and until the Sub-Adviser has reviewed and approved the materials prior to their initial use, which approval will not be unreasonably withheld or delayed. The Adviser shall indemnify and hold harmless the Sub-Adviser from any losses or costs arising from the Adviser's unauthorized use (or the Trust's or Funds' unauthorized use) of information about the Sub-Adviser, its name or logo in marketing or disclosure materials.
Sample 1
Review of Promotional Materials. On the written request of Supplier, Suneva shall provide or make available to Supplier any Suneva Promotional Materials that it intends to use for the Promotion of the Products in the Territory. Supplier shall have a reasonable opportunity to review and comment upon any such Suneva Promotional Materials to ensure that such Suneva Promotional Materials and Suneva shall consider such comments in good faith.
Sample 1
Review of Promotional Materials. Subject to applicable Law, the Parties, acting under the direction of the JSC, will jointly, through consultation and with the assistance of each other, create a mechanism (which must be consistent with the remainder of this Section 7.01) to review and approve the core Promotional Materials. The relevant legal, medical, marketing and regulatory personnel of each Party shall have the opportunity to review and comment on all such core Promotional Materials prior to use and such comments shall be considered in the review and approval of such core Promotional Materials. The specific mechanism and procedure for review shall be as follows: All proposed core Promotional Materials, academic, scientific and medical publications and public presentations relating to a Licensed Product or any research or Development activities under this Agreement will be submitted to a Promotional Review Committee (hereinafter “PRC”), for review and approval in connection with preservation of patentability and trade secrets and/or to determine whether Confidential Information should be modified or deleted from the proposed publication or public presentation. The PRC will operate in the same manner and on the same timeframes as ASTELLAS’ PRCs for other products within ASTELLAS’ portfolio. [*] from each of its [*] all materials [*] from one person [*]. The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publications relating to the Licensed Product or any Development activities under this Agreement. [*]=CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
Sample 1

Related to Review of Promotional Materials

  • Promotional Materials In the event that the Fund or the Adviser makes available any promotional materials related to the Securities or the transactions contemplated hereby intended for use only by registered broker-dealers and registered representatives thereof by means of an Internet web site or similar electronic means, the Adviser will install and maintain, or will cause to be installed and maintained, pre-qualification and password-protection or similar procedures which are reasonably designed to effectively prohibit access to such promotional materials by persons other than registered broker-dealers and registered representatives thereof.

  • Promotional Material In the event that the Fund or the Investment Adviser makes available any promotional materials related to the Securities or the transactions contemplated hereby intended for use only by registered broker-dealers and registered representatives thereof by means of an Internet web site or similar electronic means, the Investment Adviser will install and maintain or will cause to be installed and maintained, pre-qualification and password-protection or similar procedures which are reasonably designed to effectively prohibit access to such promotional materials by persons other than registered broker-dealers and registered representatives thereof.

  • Advertising and Promotional Materials The Purchaser acknowledges and agrees that the Vendor shall have the right to use drawings, photographs, videos or other depictions of the interior and/or exterior of the Dwelling and/or the Subdivision or any components or features thereof in any promotional or advertising materials without notice to or consent from the Purchaser being required in any manner whatsoever.

  • Review of Materials During the term of this Agreement, Client shall ensure that all prospectuses, statements of additional information, registration statements, proxy statements, reports to shareholders, advertising and sales literature or other materials prepared for distribution to Fund shareholders or the public, which refer to the Subadviser in any way, prepared by employees or agents of Client or its affiliates are consistent with information previously provided by Subadviser. Subadviser shall promptly notify the Client of any changes to information pertaining to the Subadviser and stated in the materials described in this Section 6(g).

  • Instructional Materials A. The Board recognizes that appropriate texts, library reference facilities, maps and globes, laboratory equipment, audio-visual equipment, art supplies, athletic equipment, current periodicals, standard tests and questionnaires, computers, and similar materials are the tools of the teaching profession. B. Efforts shall be continued to seek and use instructional materials which reflect the contribution and presence of diverse ethnic and cultural groups. C. 1. Selection of instructional materials for each school shall be made by a committee of teachers chosen by the faculty within that school.

  • Product Labeling The labeling of all Licensed Products sold or offered for sale under this Agreement shall expressly state that the Licensed Product is manufactured under a license from the Medicines Patent Pool.

  • Labeling Upon request, Lessee will xxxx the Equipment indicating Lessor's interest with labels provided by Lessor. Lessee will keep all Equipment free from any other marking or labeling which might be interpreted as a claim of ownership.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Marketing Materials (a) During the term of this Agreement, the Sub-Adviser agrees to furnish the Manager at its principal office for prior review and approval by the Manager all written and/or printed materials, including but not limited to, PowerPointÒ or slide presentations, news releases, advertisements, brochures, fact sheets and other promotional, informational or marketing materials (the “Marketing Materials”) for internal use or public dissemination, that are produced or are for use or reference by the Sub-Adviser, its affiliates or other designees, broker-dealers or the public in connection with the Series, and Sub-Adviser shall not use any such materials if the Manager reasonably objects in writing within five business days (or such other period as may be mutually agreed) after receipt thereof. Marketing Materials may be furnished to the Manager by first class or overnight mail, facsimile transmission equipment, electronic delivery or hand delivery. (b) During the term of this Agreement, the Manager agrees to furnish the Sub-Adviser at its principal office all prospectuses, proxy statements, reports to shareholders, or Marketing Materials prepared for distribution to shareholders of each Series, or the public that refer to the Sub-Adviser in any way, prior to the use thereof, and the Manager shall not use any such materials if the Sub-Adviser reasonably objects in writing within five business days (or such other period as may be mutually agreed) after receipt thereof. The Sub-Adviser’s right to object to such materials is limited to the portions of such materials that expressly relate to the Sub-Adviser, its services and its clients. The Manager agrees to use its reasonable best efforts to ensure that materials prepared by its employees or agents or its affiliates that refer to the Sub-Adviser or its clients in any way are consistent with those materials previously approved by the Sub-Adviser as referenced in the first sentence of this paragraph. Marketing Materials may be furnished to the Sub-Adviser by first class or overnight mail, facsimile transmission equipment, electronic delivery or hand delivery.

  • Regulatory Materials (a) On a Program-by-Program basis, commencing on the Effective Date until the Regulatory Transfer Date, Prothena shall have the right, in consultation with Celgene, to prepare, file and maintain all Regulatory Materials (including any Regulatory Approvals) necessary for the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program (collectively, the “Program Regulatory Materials”), and to interact with Regulatory Authorities in connection with the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program. Prothena will provide Celgene with a reasonable opportunity to comment substantively on all material Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Celgene, including with respect to filing strategy. In addition, Prothena will allow Celgene or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. (b) If Celgene exercises its Phase 1 Portion Participation Right for a given Program, then immediately after such exercise, Prothena shall initiate the transfer of all Program Regulatory Materials, including for clarity any IND for the relevant Collaboration Candidates and/or Collaboration Products that are the subject of such Program to Celgene. The date on which such Program Regulatory Materials are transferred to Celgene shall be the “Regulatory Transfer Date” for such Program. Thereafter, Celgene shall have the right, in consultation with Prothena, to prepare, file, and maintain such Program Regulatory Materials, and to interact with Regulatory Authorities in connection with the Development and, as applicable, Manufacture of such Collaboration Candidates and Collaboration Products for such Program in accordance with the terms and conditions of Section 2.5. Additionally, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will provide Prothena with a reasonable opportunity to comment substantively on all material Program Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Prothena, including with respect to filing strategy. In addition, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will allow Prothena or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. For clarity, if the Regulatory Transfer Date does not occur prior to the expiration of the Option Term for such Program, Section 2.6.1(a) (and not this Section 2.6.1(b)) shall apply.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!